Age (y)* | 36 (13.1) | 33 (10.8) | 0.44 |
Male (%) | 24 (75) | 28 (80) | 0.77 |
Race (%) | | | 0.73 |
Caucasian | 21 (66) | 26 (74) | |
Asian/Mongoloid | 7 (22) | 6 (17) | |
ALT* (×ULN) | 2.9 (1.3) | 2.9 (1.5) | 0.94 |
Log HBV DNA* | 8.9 (1.3) | 9.2 (0.9) | 0.25 |
Genotype (%) | | | 0.46 |
A | 9 (28) | 10 (29) | |
B | 2 (6) | 5 (14) | |
C | 7 (22) | 4 (11) | |
D | 11 (34) | 15 (43) | |
Pre-existing cirrhosis (%) | 5 (16) | 5 (14) | 0.99 |
Dose reduction (%) | 11 (34) | 13 (37) | 0.81 |
Discontinuation of treatment (%) | 4 (13) | 5 (14) | 0.83 |
Flares during treatment (%) | 20 (63) | 14 (40) | 0.067 |
Time of flare† | 36 (4–78) | 60 (4–78) | 0.27 |
Peak value flare* (×ULN) | 13.7 (6.9) | 16.4 (13.8) | 0.89 |
Response (%) | 10 (31) | 10 (29) | 0.81 |